Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: weight loss + pramlintide + weight  Related to the article below (Last Update: 5/12/2008)

Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical ...
PR Newswire (press release), NY - May 5, 2008
In previous clinical studies, obese subjects treated with pramlintide 360 micrograms twice daily for 1 year experienced an average weight loss of ...AMLN
Amylin Pharma Commences Phase 2B Dose-Ranging Study Of Pramlintide ...
RTT News, NY - May 5, 2008
... 2B study will bring us one step closer to our goal of offering obese individuals a safe and effective therapy that results in meaningful weight loss. ...AMLN
Event Brief of Q1 2008 Amylin Pharmaceuticals, Inc. Earnings ...
Insurance News Net (press release), PA - May 5, 2008
Weight loss. 7. Is taking action and is extremely focused on executing Co.'s commercial strategy to improve BYETTA performance. 8. ...AMLN
Amylin Starts Phase IIb Obesity Trial
RedOrbit, TX - May 6, 2008
... IIb study will bring us one step closer to our goal of offering obese individuals a safe and effective therapy that results in meaningful weight loss."AMLN
Source: Google News

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in … -
PA Hollander, P Levy, MS Fineman, DG Maggs, LZ … - Diabetes Care, 2003 - Am Diabetes Assoc
... vs. 28%, P < 0.05). The glycemic improvement with pramlintide 120 ?g BID
was accompanied by a mean weight loss (-1.4 kg vs. +0.7 ...

Effect of Pramlintide on Weight in Overweight and Obese Insulin-Treated Type 2 Diabetes Patients -
P Hollander, DG Maggs, JA Ruggles, M Fineman, L … - Obesity Research, 2004 - NAASO
... Unlike these antiobesity agents, which may improve glycemic control as a secondary
consequence of weight loss, pramlintide has a primary antihyperglycemic ...

… Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight … -
RE Ratner, LL Want, MS Fineman, MJ Velte, JA … - Diabetes Technology & Therapeutics, 2002 - liebertonline.com
... group, and two in the 150-mg pramlintide group ... is a progressive disease char- acterized
by a gradual loss of b ... risk of hypo- glycemia, 1 and undesired weight gain ...

… of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with … -
P Hollander, R Ratner, M Fineman, S Strobel, L … - Diabetes, Obesity and Metabolism, 2003 - Blackwell Synergy
... In Synergy PubMed (MEDLINE) CrossRef By keywords HbA 1c pramlintide type 2 diabetes
weight loss By author P. Hollander R. Ratner M. Fineman S. Strobel L. Shen D ...

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese … -
K Fujioka, TB Seaton, E Rowe, CA Jelinek, P Raskin … - Diabetes, Obesity and Metabolism, 2000 - Blackwell Synergy
... Weight loss with sibutramine improves glycaemic control and other metabolic parameters
in obese patients with type 2 diabetes mellitus. ... Weight Loss. ...

… Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to … -
F Whitehouse, DF Kruger, M Fineman, L Shen, JA … - Diabetes Care, 2002 - Am Diabetes Assoc
... 1c reduction was associated with an average weight loss, rather than weight gain,
and ... levels decreased rapidly in patients receiving pramlintide for the ...

… pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type … -
RE Ratner, R Dickey, M Fineman, DG Maggs, L Shen, … - Diabetic Medicine, 2004 - Blackwell Synergy
... study population based on baseline BMI indicated that the addition of pramlintide
prevented weight gain in lean patients and induced weight loss in overweight ...

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with … -
D Maggs, L Shen, S Strobel, D Brown, O Kolterman, … - Metabolism, 2003 - Elsevier
... These apparent ethnic differences in weight loss with pramlintide treatment should
be interpreted with caution, however, considering the imbalances in gender ...

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes -
I Chapman, B Parker, S Doran, C Feinle-Bisset, J … - Diabetologia, 2005 - Springer
... interpretation: The results indicate that enhanced satiety and reduced food intake
may explain the weight loss observed in long-term pramlintide trials. ...

Weight Effect of Current and Experimental Drugs for Diabetes Mellitus: From Promotion to Alleviation … -
JQ Purnell, C Weyer - Treatments in Endocrinology, 2003 - endocrinology.adisonline.com
... is unlikely to support an independent weight loss indication.[119 ... central regulation
of feeding and weight homeostasis ... Pramlintide is a synthetic analog of human ...

Source: Google Scholar
 
 

Pramlintide produces progressive weight loss

 
 
Data from a 16-week Phase II study showed that Pramlintide reduces body weight in obese subjects.

Pramlintide is a synthetic analog of human amylin, a hormone known to play a role in the regulation of appetite and food intake.

The study showed statistically significant, progressive weight loss of 3.6 percent ( 3.5 kilograms ) compared to placebo, with no evidence of a plateau in effect at 16 weeks.
The weight loss was accompanied by a significant, progressive reduction in waist circumference, a recognized marker of abdominal obesity and cardiovascular risk.

This blinded, placebo-controlled study included 204 obese subjects, 160 without diabetes and 44 with non-insulin-treated type 2 diabetes.
Study participants received Pramlintide or placebo three times a day before meals for 16 weeks and were asked to maintain their usual diet and exercise routines.

Subjects in this study were able to tolerate higher doses of Pramlintide than those previously evaluated in long-term diabetes studies, with approximately 90% progressing to 240 micrograms three times a day.

Subgroup analyses indicated that body weight reduction with Pramlintide versus placebo was most pronounced in subjects with obesity class I ( BMI of 30 to 35 kg/m2 ), who experienced an average weight loss of approximately 5 percent at 16 weeks.

Pramlintide was generally well tolerated. The most common adverse event for Pramlintide compared to placebo was mild, transient nausea, experienced by a minority of subjects.
Weight loss in subjects who did not experience nausea was similar to that seen in those who did experience nausea.

" It is clear that islet hormones can have important effects on satiety and food intake," said Jeffrey Friedman, Rockefeller University and investigator, Howard Hughes Medical Institute.

Symlin ( Pramlintide ) injection was approved by the U.S. Food and Drug Administration ( FDA ) on March 16, 2005.
Symlin is given at mealtime and is indicated for:

- Type 2 diabetes, as an adjunct treatment in patients who use mealtime Insulin therapy and have failed to achieve desired glucose control despite optimal Insulin therapy, with or without a concurrent sulfonylurea agent and/or Metformin;
- Type 1 diabetes, as an adjunct treatment in patients who use mealtime Insulin therapy and who have failed to achieve desired glucose control despite optimal Insulin therapy.


Source: European Congress on Obesity ( ECO ), 2005
 
 
 
Google
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page